These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7570508)

  • 21. Immunohistochemical detection of estrogen receptor in invasive human breast cancer: correlation with heat shock proteins, pS2 and oncogene products.
    Takahashi S; Narimatsu E; Asanuma H; Okazaki M; Okazaki A; Hirata K; Mori M; Chiba T; Sato N; Kikuchi K
    Oncology; 1995; 52(5):371-5. PubMed ID: 7637953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Estrogens and breast cancer: from action mechanisms to clinical applications].
    Garcia M; Rochefort H
    Ann Endocrinol (Paris); 1995; 56(5):543-5. PubMed ID: 8597500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor.
    Luqmani YA; Ricketts D; Ryall G; Turnbull L; Law M; Coombes RC
    Int J Cancer; 1993 Jun; 54(4):619-23. PubMed ID: 8514453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of the oestrogen responsive protein pS2 in human breast cancer.
    Balleine RL; Clarke CL
    Histol Histopathol; 1999 Apr; 14(2):571-8. PubMed ID: 10212819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity.
    Harding C; Osundeko O; Tetlow L; Faragher EB; Howell A; Bundred NJ
    Br J Cancer; 2000 Jan; 82(2):354-60. PubMed ID: 10646888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. pS2 protein and steroid hormone receptors in invasive breast carcinomas.
    Koerner FC; Goldberg DE; Edgerton SM; Schwartz LH
    Int J Cancer; 1992 Sep; 52(2):183-8. PubMed ID: 1521907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of oestrogen responsiveness of breast cancer by competitive reverse transcription-polymerase chain reaction.
    Carr M; May FE; Lennard TW; Westley BR
    Br J Cancer; 1995 Dec; 72(6):1427-34. PubMed ID: 8519655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor analysis on needle aspirates from human mammary carcinoma.
    Silfverswärd C; Humla S
    Acta Cytol; 1980; 24(1):54-7. PubMed ID: 6928336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. pS2 in breast carcinoma: association with steroid hormone receptor status.
    Nikolić-Vukosavljević D; Grujić-Adanja G; Janković R; Branković-Magić M; Polić D; Jovanović D; Mitrović L
    Tumori; 1998; 84(6):691-4. PubMed ID: 10080679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].
    Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E
    Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of pS2 expression of involved lymph nodes in relation to primary breast carcinoma.
    Nichols PH; Ibrahim NB; Padfield CJ; Cawthorn SJ
    Eur J Surg Oncol; 1995 Apr; 21(2):151-4. PubMed ID: 7720888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of pS2 mRNA in breast cancer.
    Wysocki SJ; Iacopetta BJ; Ingram DM
    Eur J Cancer; 1994; 30A(12):1882-4. PubMed ID: 7880621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours.
    Henry JA; Bennett MK; Piggott NH; Levett DL; May FE; Westley BR
    Br J Cancer; 1991 Oct; 64(4):677-82. PubMed ID: 1911216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary breast carcinoma: immunocytochemical and immunohistochemical evaluation of biological parameters.
    Sianesi M; Bozzetti C; Del Rio P; Nizzoli R; Cascinu S
    Chir Ital; 2000; 52(6):643-5. PubMed ID: 11199998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. pS2 is an independent factor of good prognosis in primary breast cancer.
    Thompson AM; Hawkins RA; Elton RA; Steel CM; Chetty U; Carter DC
    Br J Cancer; 1993 Jul; 68(1):93-6. PubMed ID: 8318427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
    Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD
    Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pS2 gene, mRNA, and protein: a potential marker for human breast cancer.
    Rio MC; Chambon P
    Cancer Cells; 1990; 2(8-9):269-74. PubMed ID: 2223388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical detection of sex steroid receptors in breast cancer using routine paraffin sections: comparison with frozen sections and enzyme immunoassay.
    Elias JM; Margiotta M; Sexton TR; Heimann A
    J Cell Biochem Suppl; 1994; 19():126-33. PubMed ID: 7823584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of the human spasmolytic polypeptide and an estrogen-induced breast cancer protein (pS2) with human pancreatic carcinoma.
    Welter C; Theisinger B; Seitz G; Tomasetto C; Rio MC; Chambon P; Blin N
    Lab Invest; 1992 Feb; 66(2):187-92. PubMed ID: 1735955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.